SCHEMBL6293201

SCHEMBL6293201

Cc1cc(CO)nc(CN2CCN(c3ccnc(CCO)n3)CC2)n1

nearest known ligand 0.55

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SORD Q00796 20/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6293340 0.92 SORD (0.60) SORD
SCHEMBL6293419 0.91 SORD (0.58) SORD
SCHEMBL6503054 0.85 SORD (0.72) SORD
SCHEMBL6294637 0.82 SORD (0.60) SORD
SCHEMBL6294424 0.82 SORD (0.65) SORD
SCHEMBL6822600 0.77 SORD (0.71) SORD
SCHEMBL7191448 0.74 SORD (0.70) SORD
SCHEMBL6822408 0.72 SORD (0.70) SORD
SCHEMBL6822454 0.72 SORD (0.66) SORD
SCHEMBL6819093 0.68 SORD (0.64) SORD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337271-B1 COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS PFIZER PROD INC (US) 2004-11-03 EP claimed
US-20040077671-A1 Sorbitol dehydrogenase inhibitors CHU-MOYER MARGARET Y (US) 2004-04-22 US claimed
US-20030212072-A1 Salts of zopolrestat MYLARI BANAVARA L (US) 2003-11-13 US claimed
US-20030186994-A1 Combination of statins and sorbitol dehydrogenase inhibitors MYLARI BANAVARA L (US) 2003-10-02 US claimed
EP-1337271-A2 COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS Pfizer Products Inc. (US) 2003-08-27 EP claimed
EP-1326591-A2 COMBINATION OF STATINS AND SORBITOL DEHYDROGENASE INHIBITORS Pfizer Products Inc. (US) 2003-07-16 EP claimed
US-6544998-B2 For treatment of suffering from diabetic complications like diabetic neuropathy, nephropathy, cardiomyopathy, retinopathy, microangiopathy, macroangiopathy, cataracts and foot ulcers. PFIZER INC 2003-04-08 US claimed
US-20030065179-A1 Sorbitol dehydrogenase inhibitors CHU-MOYER MARGARET Y (US) 2003-04-03 US claimed
WO-2002098429-A1 ETHANOLAMINE, DIETHANOLAMINE OR TRIETHANOLAMINE SALT OF ZOPOLRESTAT PFIZER PRODUCTS INC. (US) 2002-12-12 WO claimed
US-20020091128-A1 Combination of gaba agonists and sorbitol dehydrogenase inhibitors MYLARI BANAVARA L (US) 2002-07-11 US claimed
US-6414149-B1 TREATING DIABETES, TREATING OR PREVENTING DIABETIC COMPLICATIONS PFIZER INC. 2002-07-02 US claimed
WO-2002043762-A2 COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS PFIZER PRODUCTS INC. (US) 2002-06-06 WO claimed
WO-2002032411-A2 COMBINATION OF STATINS AND SORBITOL DEHYDROGENASE INHIBITORS PFIZER PRODUCTS INC. (US) 2002-04-25 WO claimed
EP-1185275-A1 AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS Pfizer Products Inc. (US) 2002-03-13 EP claimed
US-20010056095-A1 Salts of zopolrestat MYLARI BANAVARA L (US) 2001-12-27 US claimed
WO-2000059510-A1 AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS PFIZER PRODUCTS INC. (US) 2000-10-12 WO claimed
US-6936600-B2 Sorbitol dehrydrogenase inhibitors PFIZER INC (US) 2005-08-30 US disclosed
US-6869943-B2 Sorbitol dehydrogenase inhibitors PFIZER INC (US) 2005-03-22 US disclosed
US-20010056095-A1 Salts of zopolrestat MYLARI BANAVARA L (US) 2001-12-27 US disclosed
WO-2000059510-A1 AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS PFIZER PRODUCTS INC. (US) 2000-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010056095-A1 Salts of zopolrestat SLC5A1, SLC5A2, SLC2A1 SORD 14/4885
US-20030186994-A1 Combination of statins and sorbitol dehydrogenase inhibitors SORD, HMGCR, SCD SORD 1/4885
US-20040077671-A1 Sorbitol dehydrogenase inhibitors SLC5A1, SORD, SLC5A2 SORD 2/4885
US-20030212072-A1 Salts of zopolrestat SLC5A1, SLC5A2, SLC2A1 SORD 14/4885
US-20030065179-A1 Sorbitol dehydrogenase inhibitors SLC5A1, SORD, SLC5A2 SORD 2/4885
US-20020091128-A1 Combination of gaba agonists and sorbitol dehydrogenase inhibitors SORD, GABRE, SLC6A1 SORD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.